Evaluation of the Effect of Drug-Related Problems in Pulmonary Embolism

Status Completed

Clinical Trial Summary

Pulmonary embolism (PE) presents notable risks of morbidity and mortality, underscoring the need for customized anticoagulant treatment. There is a scarcity of research examining drug-related issues (DRPs) in PE. This research endeavor seeks to assess how addressing DRPs affects the clinical outcomes of PE patients receiving outpatient care, offering valuable insights to bolster patient safety measures. This study will conduct a randomized controlled trial on PE patients in Istanbul, Turkey, from January 15, 2022, to January 15, 2023. The intervention group (IG) will receive clinical pharmacist (CP) recommendations for DRPs, while the control group (CG) will undergo observation only. Evaluations will occur at 90- and 180-days post-discharge, focusing on DRPs, CP interventions, and patient outcomes. Data will be systematically recorded and analyzed, adhering to ethical standards and employing the PCNE v9.1 classification system.

Clinical Trial Description

Pulmonary embolism (PE) involves the blockage of the pulmonary artery or one of its branches by materials like thrombus from elsewhere in the body. This condition is linked to increased mortality and morbidity rates, and if left untreated, it can result in recurring episodes. Additionally, using anticoagulant therapy poses a significant risk of severe bleeding. Recent guidelines recommend customizing the duration of PE treatment based on the type of underlying risk factor, distinguishing between transient and persistent factors. Prolonged treatment without a persistent risk factor may heighten the risk of bleeding. Hence, selecting appropriate treatment options tailored to individual patient needs is crucial. The main goal of our study is to evaluate how managing drug-related problems (DRPs) in pulmonary embolism (PE) outpatients influences their clinical outcomes. This research aims to provide valuable insights into the effectiveness of interventions targeting DRPs within the framework of PE management . ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06392672
Study type	Interventional
Source	Bezmialem Vakif University
Contact
Status	Completed
Phase	N/A
Start date	January 15, 2022
Completion date	January 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06348459` - Registry of Catheter Intervention in Pulmonary Embolism
Completed	`NCT03134898` - Longitudinal Study to Identify Predictive Factors of Post-thrombotic Pulmonary Hypertension
Completed	`NCT04625673` - OsciPulse Device for the Prevention of VTE	N/A
Not yet recruiting	`NCT06382038` - Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism	N/A
Recruiting	`NCT01531829` - Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD	Phase 4
Recruiting	`NCT05719415` - Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension	N/A
Recruiting	`NCT05905874` - Machine Learning-based Models in Prediction of DVT and PTE in AECOPD Patients
Recruiting	`NCT06341231` - Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
Terminated	`NCT05172115` - Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE	Phase 3
Completed	`NCT03134820` - Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease	N/A
Completed	`NCT03183063` - Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events	N/A